

Special Issue

Advances in Clinical Trials of Hematological Malignancies

Message from the Guest Editor

During the last decade the therapy of hematologic malignancies has undergone a major expanse. Besides the conventional morfologic, immunophenotyping and cytogenetic data, we are able to perform next generation sequencing of multiple genes as well as methylation profile analyzis is possible to understand epigenetic dysregulations involved in these diseases. This large amount of information has provided us with new potential therapeutic targets, but we still have to fully understand and utilize this vast amount of information. The therapeutic utilization of chimeric receptor T and NK cells is also a rapidly expanding field achieving unprecedented results in previously refractory patients. The new clinical trials are often based on the so called "basket" approach to explore genetic and epigenetic subtypes of diseases responding to certain therapeutic agents.

A special issue of this journal will focus on this field. We aim to publish papers on novel trials, or exploring novel targeted therapies as well as in vitro trials focusing on potential new therapeutic targets.

Guest Editor

Dr. Lajos Gergely

Department of Hematology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary

Deadline for manuscript submissions

closed (15 June 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/130817

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)